PDCD1 and neoplasm: Combining immunotherapy with checkpoint inhibitors (e.g., anti-PD-1/PD-L1, anti-SIRP-α/CD47, CD40/CD40L, or anti-Siglec-10/CD24) or systemic therapies with TAM depletion aims to enhance the anti-tumor response against HCC by creating a favorable immune environment [84,85] (Figure 2 & Table 2).